Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

C Chabannon, J Kubal, A Bondanza, Francesco Dazzi, P Pedrazzoli, A Toubert, Annalisa Ruggeri, K Fleischhauer, C Bonini

Research output: Contribution to journalArticle

Abstract

Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation. Copyright © 2018, American Association for the Advancement of Science.
Original languageEnglish
Article numberaap9630
JournalScience Translational Medicine
Volume10
Issue number436
DOIs
Publication statusPublished - 2018

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell Transplantation
Biological Phenomena
Investigational Therapies
Secondary Prevention
Therapeutics
Population

Cite this

Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. / Chabannon, C; Kubal, J; Bondanza, A; Dazzi, Francesco; Pedrazzoli, P; Toubert, A; Ruggeri, Annalisa; Fleischhauer, K; Bonini, C.

In: Science Translational Medicine, Vol. 10, No. 436, aap9630, 2018.

Research output: Contribution to journalArticle

Chabannon, C, Kubal, J, Bondanza, A, Dazzi, F, Pedrazzoli, P, Toubert, A, Ruggeri, A, Fleischhauer, K & Bonini, C 2018, 'Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies', Science Translational Medicine, vol. 10, no. 436, aap9630. https://doi.org/10.1126/scitranslmed.aap9630
Chabannon, C ; Kubal, J ; Bondanza, A ; Dazzi, Francesco ; Pedrazzoli, P ; Toubert, A ; Ruggeri, Annalisa ; Fleischhauer, K ; Bonini, C. / Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. In: Science Translational Medicine. 2018 ; Vol. 10, No. 436.
@article{56d907946a424678ac8c9275c91f2a95,
title = "Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies",
abstract = "Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation. Copyright {\circledC} 2018, American Association for the Advancement of Science.",
author = "C Chabannon and J Kubal and A Bondanza and Francesco Dazzi and P Pedrazzoli and A Toubert and Annalisa Ruggeri and K Fleischhauer and C Bonini",
year = "2018",
doi = "10.1126/scitranslmed.aap9630",
language = "English",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "436",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies

AU - Chabannon, C

AU - Kubal, J

AU - Bondanza, A

AU - Dazzi, Francesco

AU - Pedrazzoli, P

AU - Toubert, A

AU - Ruggeri, Annalisa

AU - Fleischhauer, K

AU - Bonini, C

PY - 2018

Y1 - 2018

N2 - Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation. Copyright © 2018, American Association for the Advancement of Science.

AB - Over the last 60 years, more than a million patients received hematopoietic cell transplantation. Having incorporated multiple changes in clinical practices, it remains a complex procedure facing a dual challenge: cure of the underlying disease and prevention of relapse while controlling potentially severe complications. Improved understanding of underlying biological processes resulted in the design of innovative therapies engineered from defined cell populations and testing of these therapies as addition or substitution at virtually every step of the procedure. This review provides an overview of these developments, many of them now applied outside the historical field of hematopoietic cell transplantation. Copyright © 2018, American Association for the Advancement of Science.

U2 - 10.1126/scitranslmed.aap9630

DO - 10.1126/scitranslmed.aap9630

M3 - Article

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 436

M1 - aap9630

ER -